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aortic aneurysm: Results of a multicenter randomized trial
Kevin T. Stroupe, Frank A. Lederle, Jon S. Matsumura, Tassos C. Kyriakides,
Yvonne C. Jonk, Ling Ge, Julie A. Freischlag
Objective: This study was conducted to determine the costs and compara-
tive cost-effectiveness of twomethods of abdominal aortic aneurysm (AAA)
repair in the Open Versus Endovascular Repair (OVER) Veterans Affairs (VA)
Cooperative Study, a multicenter randomized trial of 881 patients.
Methods: The primary outcomes of this analysis were mean total health
care cost per life-year and per quality-adjusted life-year (QALY) from
randomization to 2 years after. QALYs were calculated from EuroQol (EQ)-
5D questionnaires collected at baseline and annually. Health care utiliza-
tion data were obtained directly from patients and from national VA and
Medicare data sources. VA costs were obtained from national VA sources
using methods previously developed by the VA Health Economics
Resource Center. Costs for non-VA care were determined from Medicare
claims data or billing data from the patient's health care providers.
Results: After 2 years of follow-up, mean life-years were 1.78 in the
endovascular repair group and 1.74 in the open repair group (difference,
0.04; 95% conﬁdence interval [CI], 0.03 to 0.09; P = .29). Mean QALYs
were 1.462 in the endovascular group and 1.461 in the open group
(difference adjusting for baseline EQ-5D score, 0.006; 95% CI, 0.038 to
0.052; P = .78). Mean graft costs were higher in the endovascular group
($14,052 vs $1363; P < .001), but length of stay was shorter (5.0 vs 10.5
days; P< .001), resulting in a lower mean cost of the hospital admission for
the AAA procedure in the endovascular repair group of $37,068 vs $42,970
(difference,$5901; 95% CI,$12,135 to$821; P = .04). After 2 years, total
health care costs remained lower in the endovascular group, but the
difference was no longer signiﬁcant ($5019; 95% CI,$16,720 to $4928; P
= .35). The probability of endovascular repair being less costly and more
effective was 70.9% for life-years and 51.4% for QALYs.
Conclusions: In this multicenter randomized trial, endovascular AAA
repair resulted in lower cost and better survival than open repair after the
initial hospitalization for repair; but after 2 years, survival, quality of life,
and costs were not signiﬁcantly different between the two treatments.
Patients with chronic obstructive pulmonary disease have shorter
survival but superior endovascular outcomes after endovascular
aneurysm repair
Moqueet A. Qureshi, Roy K. Greenberg, Tara M. Mastracci, Matthew J.
Eagleton, Adrian V. Hernandez
Objective: This study determined the effect of pulmonary disease on
outcomes after endovascular abdominal (EVAR) and endovascular thor-
acoabdominal aortic aneurysm (eTAAA) repair.q Full articles available online at www.jvascsurg.org
1078-5884/$ e see front matter
http://dx.doi.org/10.1016/S1078-5884(12)00577-1Methods: A prospective study of high-risk patients undergoing EVAR and
eTAAA repair between 1998 and 2009 was used to contrast clinical and
endovascular outcomes between patients with (group 1) and without
(group 2) chronic obstructive pulmonary disease (COPD). COPD patients
were classiﬁed in accordance with the severity of their pulmonary disease
using the Global Initiative for Chronic Obstructive Lung Disease criteria.
Survival, morphologic changes, and complications were assessed using
Cox models and life-table analyses. The cause and timing of deaths
between the groups was compared.
Results: Of 905 patients analyzed, 289 (32%) had COPD (group 1) and the
remaining patients (group 2) did not have COPD. EVAR was performed in
334 patients (37%), and fenestrated or branched devices were used in the
remaining 571 (63%). Group 1 patients were younger (73.5  6.7 vs 75.6 
8.2 years), had a better glomerular ﬁltration rate (67.8  25.8 vs 61.0 
23.3 mL/min/1.73 m2), had higher hematocrits (41.6  5.0 vs 40.5  4.6),
and had more extensive aneurysms. Mean follow-up was 39.5  30.9
months. Early (3% vs 3%) and late (2% vs 1%) aneurysm-related deaths were
similar between the two groups. Survival in group 1 depended on the
severity of disease. Survival in patients with Global Initiative for Chronic
Obstructive Lung Disease classiﬁcation I and II was similar to group 2.
Those with classiﬁcations III and IV demonstrated lower survival rates.
Relevant pulmonary function test variables included a lower forced expi-
ratory volume in 1 second and forced expiratory ﬂow in the middle 50%,
which were associated with decreased survival. Surrogate endovascular
outcome analyses demonstrated that group 1 patients had fewer endo-
leaks (20% vs 25%; P ¼ .05) and more rapid sac shrinkage rate (1.66 mm/y
difference; P < .001).
Conclusions: The perioperative risk of death between COPD patients and
non-COPD patients is eliminated when endovascular techniques are used.
Long-term survival in COPD patients is most strongly related to the
severity of their disease, and forced expiratory volume in 1 second and
forced expiratory ﬂow in the middle 50% are reasonable indicators of poor
long-term outcomes. Morphologic changes after EVAR and eTAAA repair
are more favorable in COPD patients, with a lower endoleak rate and faster
sac shrinkage.
Estimating the risk of solid organ malignancy in patients
undergoing routine computed tomography scans after endovascular
aneurysm repair
Raghu Motaganahalli, Angela Martin, BeeJay Feliciano, Michael P. Murphy,
James Slaven, Michael C. Dalsing
Objective: Computed tomography (CT) scans are routinely used for graft
surveillance in patients who have had endovascular repair (EVAR) of an
abdominal aortic aneurysm. There is a growing concern for cancers asso-
ciated with inadvertent use of CT scans. We report the estimated risk of
radiation associated solid organmalignancy caused by routine surveillance
CT after EVAR using the Biological Effects of Ionizing Radiation (BEIR VII)
Abstracts / European Journal of Vascular and Endovascular Surgery 44 (2012) 458e460 459model created by U.S. National Institute of Science and National Research
Council.
Methods: Our study estimated the excess relative risk (ERR) of a patient
acquiring a solid organ malignancy secondary to radiation exposure from
postoperative EVAR surveillance CT imaging. The radiation dose was
calculated in sieverts (Sv). The ERR of solid organ malignancy, as given by
the BEIR VII model, is = bs D exp {ge*} (a/60)
h, where bs, g, and h are data-
derived parameters, e is age at exposure, and e* = (e-30)/10 for e < 30 and
zero for e  30, a is attained age, and D is dose in sieverts. Dose-weighted
ERRs were calculated to allow a comparison of malignancy risk when using
a CT at all time points (model 1: 0, 1, 6, 12, and 18 months, 2, 3, and 4 years,
and yearly thereafter) vs replacing the CT scan with two other models
(model 2: CT once in 3 years) and (model 3: CT once in 5 years). The risk
was stratiﬁed by age groups, sex, and use of two different radiation doses
(15 or 31 mSv) per CT scan. Statistical analysis used the paired t test.
Results: There were signiﬁcant differences between the ERR of solid organ
malignancy in those patients who would undergo surveillance CTs at all
time points vs thosewhose surveillance consisted of alternative modalities
at some time points (P < .0001). The cumulative ERR of cancer from
radiation was higher in those exposed to contrast-enhanced CT scans,
younger people, with highest in the group aged 50 to 55 years (ERR, 0.43),
and lowest in patients aged 80 years (ERR, 0.10).
Conclusions: Patients undergoing routine CT scans for postoperative
surveillance after EVAR are at risk for acquiring new solid organ malig-
nancy due to radiation exposure. The risk is higher in young patients,
women, and those exposed to multiple contrast-enhanced CT scans. Our
analysis questions the need for routine surveillance CT scans after EVAR in
the absence of endoleaks or a change in aneurysm morphology, based on
an increased malignancy risk.
Direct percutaneous sac injection for postoperative endoleak
treatment after endovascular aortic aneurysm repair
Heiko Uthoff, Barry T. Katzen, Ripal Gandhi, Constantino S. Peña, James F.
Benenati, Philipp Geisbüsch
Background: This study presents the short-term and midterm results of
direct percutaneous sac injection (DPSI) for postoperative endoleak
treatment after endovascular aortic aneurysm repair (EVAR).
Methods: Between March 1994 and November 2011, EVAR was performed
in 986 patients. The median follow-up was 63 ± 45 months (range, 0-211
months). A retrospective analysis was performed. DPSI was used in 21
patients for 19 type II endoleaks and two endoleaks of undeﬁned origin
(EOUO), of which 12 (57%) were after failure of a previous endovascular
treatment attempt.
Results: DPSI using thrombin (n = 16), coils (n = 7), gelfoam (n = 6), or glue
(n = 3), or a combination, was technically feasible in all patients. Saccog-
raphy during DPSI revealed a previously undetected type I endoleak in
three patients. Immediate DPSI success was achieved in 16 of 18 proce-
dures (88.9%), with two complications. Glue incidentally intravasated in
the inferior vena cava, causing a clinically nonsigniﬁcant subsegmental
pulmonary artery embolism in one patient, and the temporary develop-
ment of a type III endoleak, possibly from graft puncture, in another.
During a median follow-up of 39 months (interquartile range, 13-88
months) after DPSI, recurrent endoleaks were observed in nine patients
(50.0%), one type I endoleak due to graft migration, ﬁve type II endoleaks,
and three EOUO. The occurrence of a re-endoleak during follow-up was
signiﬁcantly associated with dual antiplatelet medication (0% in patients
without re-endoleak vs 44.4% in patients with re-endoleak; P = .023) and
with a nonsigniﬁcant trend for the use of aspirin alone (33.3% in patients
without re-endoleak vs 80% in patients with re-endoleak; P = .094). Re-
endoleak occurred in 33.3% of the patients without antiplatelet medication
and in 100% of patients with dual-antiplatelet medication (P = .026).
Thrombin was used as the sole embolic agent during the initial DPSI in all
patients with dual-antiplatelet therapy. No other factor was signiﬁcantly
associated with re-endoleaks. Reinterventionwas deemed necessary in six
patients within a median of 10 months (interquartile range, 4-16 months)
after DPSI, including six additional DPSI treatments in four patients with
type II re-endoleaks, cuff placements in one type I endoleak, and endograft
relining in one EOUO.Conclusions: This initial experience suggests that DPSI is feasible as
a technique for endoleak treatment after EVAR. However, complications
and endoleak recurrence remain a concern. The role of antiplatelet therapy
and different embolic agents on long-term embolization success needs to
be studied in more detail.
Impact of preoperative embolization on outcomes of carotid body
tumor resections
Adam H. Power, Thomas C. Bower, Jan Kasperbauer, Michael J. Link,
Gustavo Oderich, Harry Cloft, William F. Young, Peter Gloviczki
Objectives: This study assessed neurovascular complications in the
surgical management of carotid body tumors (CBTs), with emphasis on
those treated with and without preoperative embolization.
Methods: We reviewed the clinical data of all consecutive patients with
CBTs treated by surgical resection at our institution from 1985 to 2010.
Outcomes were compared between Shamblin class II and III CBTs treated
with preoperative embolization (EMB group) and with no preoperative
embolization (NEMB group).
Results: A total of 131 patients (80 women, 51 men), who were aged 48
years (range, 16-84 years), had resection of 144 CBTs and 12 concurrent
cervical paragangliomas. This included 18 patients who had bilateral
resections and 29 with familial CBTs. Succinate dehydrogenase (SDHx)
mutations were conﬁrmed in 17 patients. Mean tumor volume was 20.5
cm3 (range, 0.8-101.3 cm3), and there were two biochemically active CBTs
(1%). There were 71 Shamblin II and 33 Shamblin III. The EMB group
underwent 33 CBT resections, and the NEMB group underwent 71. There
were more patients in the EMB group with bilateral (48% vs 22%; P = .01)
and familial (34% vs 14%; P = .01) CBT; otherwise, patient demographics,
Shamblin class, and tumor diameter and volumes were similar. No strokes
or other major complications occurred after preoperative embolization
with polyvinyl alcohol particles 1 day before surgery. The EMB group
required less extensive procedures (simple excision in 97% vs 82%, P = .03;
internal carotid artery clamping in 15% vs 37%, P = .04) and had less blood
loss (mean estimated blood loss, 263 vs 599 mL; P = .002) than the NEMB
group. However, there were no signiﬁcant differences in operative time
(250 vs 265 minutes; P = .49), temporary cranial nerve injury (52% vs 38%;
P = .21), clinically apparent cranial nerve deﬁcits after 1 year (12% vs 7%; P =
.46), deaths (0% vs 0%; P > .99), stroke (0% vs 1%; P > .99), or postoperative
length of stay (4.1 vs 4.2 days; P = .91).
Conclusions: Large CBTs can be resected safely with or without preoper-
ative embolization. Preoperative embolization may simplify the conduct of
the operation and reduce blood loss but does not decrease rates of cranial
nerve injury, although most are temporary.
Risk factors for clinical failure after stent graft treatment for
femoropopliteal occlusive disease
Paul C. Johnston, Shant M. Vartanian, Sara J. Runge, Jade S. Hiramoto,
Charles M. Eichler, Christopher D. Owens, Darren B. Schneider, Michael S.
Conte
Objective: Optimal selection of a revascularization strategy in femo-
ropopliteal occlusive disease (FPOD) remains controversial. Among endo-
vascular treatment options for FPOD, covered stent placement has become
increasingly used. We sought to examine the inﬂuence of clinical,
anatomic, and device-related characteristics on the clinical performance of
these devices.
Methods: This was a retrospective, single-center study of consecutively
treated limbs that underwent Viabahn (W. L. Gore, Flagstaff, Ariz) stent
graft placement for FPOD from 2005 to 2010. Clinical, anatomic, and
device-related characteristics were obtained from review of medical
records and angiograms. End points were occurrence of any reinterven-
tion, major adverse limb event (eg, major amputation, thrombolysis/
thrombectomy, or open bypass surgery), or thrombolysis/thrombectomy
treatment alone. Univariate predictors were calculated and multivariate
models constructed for each clinical end point using Cox proportional
hazards models.
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a median follow-up time of 382 days. The indication for intervention was
claudication in 56%. In 25 cases (29%), the index procedure was
a secondary intervention for FPOD, including treatment of in-stent reste-
nosis in 22 cases (25%). Lesions treated included 45% TransAtlantic Inter-
Society Consensus (TASC) II D and 58% chronic total occlusions. The
observed Kaplan-Meier 1-year event rates for reintervention, major
adverse limb event (MALE), and thrombolysis were 43%, 28%, and 17%,
respectively. MALE occurred in 18 patients, nine of whom presented with
acute limb ischemia; no patient underwent major amputation. Univariate
predictors of negative outcomes included lack of dual-antiplatelet usage,
advanced TASC II classiﬁcation, smaller implant diameter, increased
number of devices used, longer total implant length, and coverage of
a patent distal collateral vessel. Multivariate analysis demonstrated that
the presence of dual-antiplatelet usage was protective against all three
outcomes, 5-mm device diameter was a risk factor for both reintervention
and MALE, and the use of multiple devices and distal collateral coverage
were signiﬁcant risk factors for thrombolysis events.
Conclusions: Reintervention is common in the ﬁrst year after Viabahn
placement for FPOD, with more than half of the events being a MALE.
Procedural factors such as antiplatelet therapy, stent graft diameter,
implant length/number, and distal collateral coverage are strongly asso-
ciated with adverse clinical outcomes. These factors should be carefully
considered to optimize patient selection and intraoperative decision
making for this procedure.
Inﬂuence of high-heeled shoes on venous function in young women
Wagner Tedeschi Filho, Nei R.A. Dezzotti, Edvaldo E. Joviliano, Takachi
Moriya, Carlos Eli Piccinato
Background: Walking with high-heeled shoes is a common cause of
venous complaints such as pain, fatigue, and heavy-feeling legs. The aim of
the study was to clarify the inﬂuence of high-heeled shoes on the venous
return and test the hypothesis that women wearing different styles of
high-heeled shoes present an impaired venous return when compared
with their values when they are barefoot.
Methods: Thirty asymptomatic women (mean age, 26.4 years) wearing
appropriately sized shoes were evaluated by air plethysmography (APG),
a test that measures changes in air volume on a cuff placed on the calf,
while they performed orthostatic ﬂexion and extension foot movements
and altered standing up and lying down. The test was repeated in four
situations: barefoot (0 cm), medium heels (3.5 cm), stiletto high heels (7
cm), and platform high heels (7 cm). The APG values of venous ﬁlling index
(VFI), ejection fraction (EF), and residual volume fraction (RVF) were
divided into four groups according to heel height and compared by
repeated-measures analysis of variance.
Results: RVF was increased in the groups wearing high heels (stiletto and
platform) compared with the barefoot group (P < .05). RVF was increased
in themedium-heel group (3.5 cm) compared with the barefoot group (P<
.05), and despite the lack of statistical signiﬁcance, the medium-heel group
showed lower values of RVF compared with the two high-heel groups. The
EF parameter followed the opposite tendency, showing higher values forthe barefoot group compared with the other three groups (P < .05). Values
for VFI were similar in the three situations evaluated.
Conclusions: High heels reduce muscle pump function, as demonstrated
by reduced EF and increased RVF values. The continuous use of high heels
tends to provoke venous hypertension in the lower limbs and may
represent a causal factor of venous disease symptoms.
Critical analysis of renal duplex ultrasound parameters in detecting
signiﬁcant renal artery stenosis
Ali F. AbuRahma, Mohit Srivastava, Albeir Y. Mousa, David D. Dearing,
Stephen M. Hass, James R. Campbell, L. Scott Dean, Patrick A. Stone, Tammi
Keiffer
Background: Several published studies have reported differing results of
renal duplex ultrasound (RDU) imaging in detecting signiﬁcant renal
artery stenosis (RAS) using different Doppler parameters. This study is the
largest to date to compare RDU imaging vs angiography and assess various
published Doppler criteria.
Methods: RDU imaging and angiography were both done in 313 patients
(606 renal arteries). RAS was classiﬁed as normal, <60%, 60% to 99%, and
occlusion. Main outcome measurements included renal peak systolic
velocity (PSV), systolic renal-to-aortic ratio (RAR), end-diastolic velocity
(EDV), and kidney lengths.
Results: The mean PSVs and RARs for normal, <60%, and 60% stenosis
were 173, 236, and 324 cm/s (P < .0001), and 2.2, 2.9, and 4.5, respectively
(P< .0001). The PSV cutoff value that provided the best overall accuracy for
60% stenosis was 285 cm/s, with a sensitivity, speciﬁcity, and overall
accuracy of 67%, 90%, and 81%, respectively. The RAR cutoff value with the
best overall accuracy for 60% stenosis was 3.7, with a sensitivity, speci-
ﬁcity, and overall accuracy of 69%, 91%, and 82%, respectively. A PSV of
180 cm/s and RAR of 3.5 had a sensitivity, speciﬁcity, and overall
accuracy of 72%, 81%, and 78% in detecting 60% stenosis. A PSV of 200
cm/s with an RAR of3.5 had a sensitivity, speciﬁcity, and overall accuracy
of 72%, 83%, and 78% in detecting 60% stenosis. A receiver operator
characteristic (ROC) curve analysis showed that the PSV and RAR were
better than the EDV in detecting 60% stenosis: PSV area under the curve
(AUC) was 0.85 (95% conﬁdence interval [CI], 0.81-0.88), EDV AUCwas 0.71,
and RAR AUC was 0.82 (PSV vs EDV, P< .0001; PSV vs RAR, P = .075; EDV vs
RAR, P< .0001). A PSV of 285 cm/s or RAR of 3.7 alone were better than any
combination of PSVs, EDVs, or RARs in detecting 60% stenosis. The mean
kidney length was 10.4 cm in patients with 60% stenosis vs 11.0 cm in
patients with <60% stenosis (P < .0001). Twelve percent of patients with
60% stenosis had a kidney length of 8.5 cm vs 4% in patients with <60%
stenosis (P = .0003), and 5.6% (34 of 606) had accessory renal arteries on
angiography, with six detected on RDU imaging. The presence of accessory
renal arteries, solitary kidneys, or renal ﬁbromuscular dysplasia had no
inﬂuence on overall accuracy of using PSV values for detecting 60%
stenosis.
Conclusions: A PSV of 285 cm/s or an RAR of 3.7 alone can be used in
detecting 60% RAS. Previously published data must be validated in
individual vascular laboratories.
